Therapeutic Solutions International, Inc., to Initiate Clinical Trial of Patented Cancer Immunotherapy Adjuvant Nanostilbene
May 15 2018 - 9:00AM
InvestorsHub NewsWire
Therapeutic Solutions International,
Inc., to Initiate Clinical Trial of Patented
Cancer Immunotherapy Adjuvant Nanostilbene
Oceanside, CA -- May
15, 2018 -- InvestorsHub NewsWire --
Therapeutics Solutions
International, Inc., (OTC
Markets:
TSOI)
announced today Institutional Review Board (IRB)
clearance to initiate a pilot pharmacokinetic trial of its
nanoparticle delivered pterostilbene product called
"NanoStilbene."
Pterostilbene has been demonstrated
in numerous
publications, summarized at
www.projuvenol.com/lit to possess therapeutic effects in
animal models of numerous inflammatory-associated conditions
including cancer, diabetes, and heart failure. One of the
limitations of clinically developing pterostilbene is delivering
enough of the
product to the cells that need it, the Company hopes to overcome this by
the use of nanoparticles.
"The initiation of a formal clinical
trial evaluating the efficacy of the nanoparticles in
NanoStilbene is a
major milestone in the development of our product. Only through
solid science can we be positioned to state exactly the advantages
of the nano-formulation technology utilized in the manufacture of
NanoStilbene," said Timothy Dixon, President, and CEO
of Therapeutic Solutions International.
The Company currently holds an issued
US Patent on increasing efficacy of cancer immunotherapies using
pterostilbene and nanoformulations including those utilized in the
manufacture of NanoStilbene.
"Clinical trials are a fundamental
part of developing any therapeutic agent. I am excited to be
working with the Company on performing clinical trials on a
nutraceutical, which demonstrates to me the commitment Therapeutic
Solutions International has to develop superior nutraceuticals that
can be integrated into standard medical practice," said Dr. James Veltmeyer, member of
the Company's Advisory Board and Medical Monitor of the clinical
study.
About Therapeutic Solutions
International, Inc.
Therapeutic Solutions
International is focused on immune modulation for the treatment of
several specific diseases. Immune modulation refers to the ability
to upregulate (make more active) or downregulate (make less active)
one's immune system. The Company's corporate website is www.therapeuticsolutionsint.com.
Safe Harbor
Statement
This release contains forward-looking
statements that are based upon current expectations or beliefs, as
well as a number of assumptions about future events. Although we
believe that the expectations reflected in the forward-looking
statements and the assumptions upon which they are based are
reasonable, we can give no assurance that such expectations and
assumptions will prove to have been correct. Forward-looking
statements are generally identifiable by the use of words like
"may," "will," "should," "could," "expect," "anticipate,"
"estimate," "believe," "intend," or "project" or the negative of
these words or other variations on these words or comparable
terminology. The reader is cautioned not to put undue reliance on
these forward-looking statements, as these statements are subject
to numerous risk factors as set forth in our SEC filings. To the
extent that statements in this press release are not strictly
historical, including statements as to product launch timing,
revenue projections, business strategy, outlook, objectives, future
milestones, plans, intentions, goals, future collaboration
agreements, or otherwise as to future events, such statements are
forward-looking, and are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
The forward-looking statements contained in this release are
subject to certain risks and uncertainties that could cause actual
results to differ materially from the statements
made.
CONTACT
INFORMATION
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Apr 2023 to Apr 2024